Abstract: The present invention relates to the compounds of formula (I) below: wherein: X represents an oxygen atom, a sulfur atom, a nitrogen atom or a CH radical, The bond X—Y and Y are absent if X represents an oxygen or sulfur atom, the bond X—Y and Y are present if X represents a nitrogen atom or a CH radical, When present, Y represents a group R if X represents a nitrogen atom, a hydrogen atom or a group —NR1R2 if X represents a CH radical, (Het)Ar is an aromatic ring selected from the group consisting of aryl and heteroaryl groups, R3, R4, R5, R6 represent, independently of one another, a hydrogen atom, a halogen atom, a —NR12R13, a —SR14 group, a —OR14 group or a —CF3 group, When Y is —NR1R2, the groups —NR1R2 and (Het)Ar are in the cis-conformation, or a pharmaceutically acceptable salt thereof, for use in the treatment of proliferative diseases, infectious diseases, allergies, inflammation and/or asthma.

Abstract: This invention encompasses proteic binding partners of Translationally Controlled Tumor Protein (TCTP), which can modulate tumor reversion or cell apoptosis. Methods of screening for compounds useful for treating, preventing or managing cancer, an inflammatory disorder, or a neurodegenerative disorder and use of these compounds are also encompassed.

Abstract: The invention concerns genes involved in the molecular paths for tumor suppression and/or resistance to viruses, and whereof the cell expression is in particular induced or inhibited during apoptosis and/or tumor suppression.

Abstract: This invention is directed to sequences that are involved in the molecular pathways of tumor suppression, tumor revision, apoptosis and/or virus resistance. The use of the compounds having these sequences, or encoded by them, in treating cancer, neurodegenerative diseases or viral diseases, and screening methods for compounds having such therapeutic properties are also encompassed.

Abstract: Mice that are deficient in p53 are found to have memory disorders and/or behavioral disorders such as increased anxiety. A method of using p53-deficient mice to screen compounds for memory restoring activity and/or anti-anxiety activity is described.

Abstract: This invention encompasses sequences of nucleic acids and polypeptides that are involved in the regulation of tumor suppression and apoptosis and methods of using the sequences. Methods of identification for compounds that are effective in treating disorders such as cancer and neurodegenerative disease are also disclosed.

Abstract: This invention is directed to sequences that are involved in the molecular pathways of tumor suppression, tumor reversion, apoptosis and/or virus resistance. The use of the compounds having these sequences, or encoded by them, in treating cancer, neurodegenerative diseases or viral diseases, and screening methods for compounds having such therapeutic properties are also encompassed.

Abstract: This invention encompasses methods of screening the compounds that are involved in the regulation of tumor suppression and apoptosis based on the interaction between Siah and Numb proteins.

Abstract: The invention concerns methods for detecting, identifying and/or screening compounds in particular for use in treating cancers and certain neurodegenerative diseases related to dysfunction in tumour suppression regulation and/or apoptosis, in the biological chain of p53, said methods being based on interaction between TSAP6 and its binding partners identified in the present invention.

Abstract: Composition and methods of treating, preventing, and managing cancer by inhibiting the expression of the gene tpt1 are disclosed. In addition, a method of identifying genes that are involved in the tumor reversion of two or more types of cancers is also disclosed.

Abstract: Methods of treating and managing cancer are disclosed, which comprise the administration of an antihistaminic agents or structurally/functionally related to compound, optionally in combination with one or more additional anti-cancer agents. Pharmaceutical compositions, including single unit dosage forms, and kits useful in the treatment and management of cancer are disclosed. Also disclosed is a method of determining effectiveness of a cancer treatment.

Abstract: A compound that inhibits the cellular expression of a nucleotide sequence corresponding to all or part of the presenilin 1 gene, the compound comprising an antisense molecule comprising the antisense of a polynucleotide sequence selected from the group consisting of the entire polynucleotide sequence of the presenilin 1 gene, a fragment of the sequence of the presenilin 1 gene, the promoter or other regulatory sequence of the presenilin 1 gene and a polynucleotide sequence that is at least 90% homologous to the polynucleotide sequence of the presenilin 1 gene is described. Pharmaceuticals containing and methods of inhibiting the presenilin 1 gene using such compound are also described. A compound and method of inhibiting the expression product of the presenilin 1 gene also is described. A method of treating a patient having a condition characterized by excessive cell growth also is described. A method of diagnosing cancer also is described.

Abstract: The present invention relates to the use of a compound inhibiting the expression of the TPT1 gene, or of the products which it controls, for producing a drug which is intended for treating cancer.

Abstract: Tumor Suppressor Activated Pathway (TSAP) genes and nucleotide sequences therefore as well as vectors and cells containing such nucleotide sequences and various uses therefore are described. The mechanism by which TSAP 3 activates apoptosis also is described. Pharmaceutical compositions and methods for preventing tumorigenesis also is described.

Abstract: The present invention relates to the use of a compound inhibiting the expression of the TPT1 gene, or of the products which it controls, for producing a drug which is intended for treating cancer.